Back to Search Start Over

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG

Authors :
Schadendorf, D.
Ugurel, S.
Schuler-Thurner, B.
Nestle, F.O.
Enk, A.
Bröcker, E.-B.
Grabbe, S.
Rittgen, W.
Edler, L.
Sucker, A.
Zimpfer-Rechner, C.
Berger, T.
Kamarashev, J.
Burg, G.
Jonuleit, H.
Tüttenberg, A.
Becker, J.C.
Keikavoussi, P.
Kämpgen, E.
Schuler, G.
Source :
Annals of Oncology; April 2006, Vol. 17 Issue: 4 p563-570, 8p
Publication Year :
2006

Abstract

Background:This randomized phase III trial was designed to demonstrate the superiority of autologous peptide-loaded dendritic cell (DC) vaccination over standard dacarbazine (DTIC) chemotherapy in stage IV melanoma patients.

Details

Language :
English
ISSN :
09237534 and 15698041
Volume :
17
Issue :
4
Database :
Supplemental Index
Journal :
Annals of Oncology
Publication Type :
Periodical
Accession number :
ejs53416152
Full Text :
https://doi.org/10.1093/annonc/mdj138